Affiliations
PharmAla's Global Affiliates
Throughout our pursuit of Novel Chemical Entities (NCEs) based on the MDXX class of molecules, we found a global shortage of clinical-grade MDMA drug products. PharmAla believes that researchers and clinicians need access to the highest-quality supply of clinical-grade Active Pharmaceutical Ingredients (APIs) to innovate. PharmAla proudly supplies dozens of institutions and organizations dedicated to the medical use of MDMA to treat a wide range of disorders and indications.
Our Affiliates
The University of California is the world's leading public research university system.
- PharmAla was selected as the MDMA manufacturing partner for a human MDMA trial at a campus of the University of California.
- This is the first US-based Clinical Trial to utilize PharmAla's LaNeo™ MDMA.
Founded in 1850, The University of Sydney is one of the top universities in Australia.
- This trial will examine whether MDMA can enhance outcomes for patients with alcohol use disorders and Post Traumatic Stress Disorder (PTSD)
The University of Texas, San Antonio, hosts world-class educators, cutting-edge researchers and dedicated mentors. By fostering innovation and involving students in rich learning opportunities, UTSA faculty are cultivating the talent of tomorrow.
- The contract envisions the creation of a new dosage form for LaNeo™ MDMA, which will subsequently be tested in an investigator-initiated human clinical trial.
McLean Hospital, which contains the largest neuroscientific and psychiatric private research program of any private psychiatric hospital in the United States. As an affiliate of Harvard Medical School, McLean Hospital has a direct line to the most cutting-edge medical research in the world.
Monash University is a modern, global, research-intensive university, delivering education and research excellence in Australia and across the Indo-Pacific.
The mission of Johns Hopkins Medicine is to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care.
Sinai Health is a leading academic health science centre and a trailblazer for integrated care across the health continuum. Our fusion of science, innovation, care and learning has earned us international, national and provincial leadership for unique programs and compassionate care.
Numinus exists to help the world heal, starting with addressing the global crisis in mental health by harnessing the power and promise of psychedelic medicine.
Orygen’s research is world-leading, impactful and creates change. Working directly with young people, their families and friends, they pioneer new, positive approaches to the prevention and treatment of mental disorders.
Filament Health is a clinical-stage natural psychedelic drug development company.
Incannex is a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid drugs and psychedelic medicine therapies.
Awakn is a Clinical Stage Biotechnology Company Developing Therapeutics for Substance Use and Mental Health Disorders.
Emyria is dedicated to developing groundbreaking therapies that address unmet patient needs and elevate the standard of mental health care.